Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

With previous p53 drugs encountering serious side effects it would have been irresponsible to start out the kevetrin ph1 safety trial with high dosages. In retrospect it's easy to say now, but, at the time of the kevetrin trial design there had to have been a major concern with the FDA. I doubt higher or more frequent dosing would have been allowed.

That's why to dosage was increased so slowly as the trial proceeded. Many seem to forget this issue.





In Reply to 'To infinity and beyond!'
before we move onto post K stuff: recently suggested here that "continuous IV dosing "was the wrong topic, when this very same idea was proposed by critique author- you know K IV dosing via pump!

OF COURSE this is all now superceded and moot by the development of oral dosing

It does not change the past facts

That is , if anyone has a memory here, or has carefully followed the discussion